LLY

1,160.91

-0.46%↓

JNJ

233.45

+0.31%↑

ABBV

225.14

+0.46%↑

UNH

412.56

+2.41%↑

MRK

119.25

-1.47%↓

LLY

1,160.91

-0.46%↓

JNJ

233.45

+0.31%↑

ABBV

225.14

+0.46%↑

UNH

412.56

+2.41%↑

MRK

119.25

-1.47%↓

LLY

1,160.91

-0.46%↓

JNJ

233.45

+0.31%↑

ABBV

225.14

+0.46%↑

UNH

412.56

+2.41%↑

MRK

119.25

-1.47%↓

LLY

1,160.91

-0.46%↓

JNJ

233.45

+0.31%↑

ABBV

225.14

+0.46%↑

UNH

412.56

+2.41%↑

MRK

119.25

-1.47%↓

LLY

1,160.91

-0.46%↓

JNJ

233.45

+0.31%↑

ABBV

225.14

+0.46%↑

UNH

412.56

+2.41%↑

MRK

119.25

-1.47%↓

Kodu・Aktsiate loetelu・Incyte Corp
Search

Incyte Corp

Avatud

SektorTervishoid

102.92 1.42

Osta

Hinna uuendus 9. juuni 2026, 14:57 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

98.54

Max

103.53

Põhinäitajad

By Trading Economics

Sissetulek

4.1M

303M

Müük

-234M

1.3B

P/E

Sektori keskmine

13.501

49.888

Aktsiakasum

1.81

Kasumimarginaal

23.834

Töötajad

2,844

EBITDA

-47M

368M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+9.36% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

28. juuli 2026

Turustatistika

By TradingEconomics

Turukapital

49M

19B

Eelmine avamishind

101.5

Eelmine sulgemishind

102.92

Uudiste sentiment

By Acuity

47%

53%

151 / 344 Pingereas Healthcare

Incyte Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. juuni 2026, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

DJ

Loe

8. juuni 2026, 15:41 UTC

Suurimad hinnamuutused turgudel

American Battery Shares Jump on Energy Department Victory

DJ

Loe

8. juuni 2026, 23:46 UTC

Market Talk

Nikkei May Rebound After Monday's Selloff -- Market Talk

DJ

Loe

8. juuni 2026, 23:37 UTC

Market Talk

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

DJ

Loe

8. juuni 2026, 23:25 UTC

Market Talk

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

DJ

Loe

8. juuni 2026, 23:25 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Loe

8. juuni 2026, 21:57 UTC

Omandamised, ülevõtmised, äriostud

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

DJ

Loe

8. juuni 2026, 21:56 UTC

Omandamised, ülevõtmised, äriostud

Salesforce Agrees to Buy m3ter

DJ

Loe

8. juuni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

DJ

Loe

8. juuni 2026, 19:22 UTC

Market Talk

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

DJ

Loe

8. juuni 2026, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

DJ

Loe

8. juuni 2026, 18:52 UTC

Market Talk

Global Energy Roundup: Market Talk

DJ

Loe

8. juuni 2026, 18:52 UTC

Market Talk

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

DJ

Loe

8. juuni 2026, 18:17 UTC

Market Talk

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

DJ

Loe

8. juuni 2026, 17:32 UTC

Market Talk

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

DJ

Loe

8. juuni 2026, 17:29 UTC

Market Talk

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

DJ

Loe

8. juuni 2026, 17:29 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Loe

8. juuni 2026, 16:55 UTC

Omandamised, ülevõtmised, äriostud

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

DJ

Loe

8. juuni 2026, 16:54 UTC

Omandamised, ülevõtmised, äriostud

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

DJ

Loe

8. juuni 2026, 16:40 UTC

Market Talk

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

DJ

Loe

8. juuni 2026, 16:31 UTC

Market Talk

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

DJ

Loe

8. juuni 2026, 16:27 UTC

Market Talk

Mexican Inflation Seen Easing in May -- Market Talk

DJ

Loe

8. juuni 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

DJ

Loe

8. juuni 2026, 16:03 UTC

Omandamised, ülevõtmised, äriostud

Orange Bought Stake From Lorca

DJ

Loe

8. juuni 2026, 16:01 UTC

Omandamised, ülevõtmised, äriostud

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

DJ

Loe

8. juuni 2026, 16:01 UTC

Omandamised, ülevõtmised, äriostud

Orange Acquires 100% Ownership of MasOrange

DJ

Loe

8. juuni 2026, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Loe

8. juuni 2026, 15:58 UTC

Market Talk

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

DJ

Loe

8. juuni 2026, 15:55 UTC

Market Talk

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

DJ

Loe

8. juuni 2026, 15:41 UTC

Market Talk

Gold Falls Below 200-Day Moving Average -- Market Talk

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

Incyte Corp Prognoos

Hinnasiht

By TipRanks

9.36% tõus

12 kuu keskmine prognoos

Keskmine 110.06 USD  9.36%

Kõrge 135 USD

Madal 75 USD

Põhineb 19 Wall Streeti analüütiku instrumendi Incyte Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

19 ratings

8

Osta

10

Hoia

1

Müü

Põhineb 19 analüütiku instrumendi Incyte Corp aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

151 / 344 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation

Muud aktsiad sektorist

LLY

Eli Lilly and Co.

1,160.91

↓-0.46%

JNJ

Johnson and Johnson

233.45

↑ +0.31%

ABBV

AbbVie Inc

225.14

↑ +0.46%

UNH

UnitedHealth Group Inc

412.56

↑ +2.41%

MRK

Merck & Co Inc.

119.25

↓-1.47%
help-icon Live chat